ArticleFrontiers in neuroscience2018
Alzheimer Disease and Selected Risk Factors Disrupt a Co-regulation of Monoamine Oxidase-A/B in the Hippocampus, but Not in the Cortex.
Article in Frontiers in neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 49 citations in OpenAlex.
- The role of 2-Oxoglutarate dehydrogenase complex mitochondrial enzyme in alzheimer's disease: a literature review and bioinformatics workflow.Metabolic brain disease · 2026Review
- Dual-Emission Fluorescent Probe for Simultaneous Visualization of Monoamine Oxidase A and Lysyl Oxidase in Alzheimer's Disease Cell Models.Chemical & biomedical imaging · 2026Article
- d‑Glucose-Conjugated Benzo[ACS medicinal chemistry letters · 2025Article
- Exploring the Benzazoles Derivatives as Pharmacophores for AChE, BACE1, and as Anti-Aβ Aggregation to Find Multitarget Compounds against Alzheimer's Disease.Molecules (Basel, Switzerland) · 2024Review
- Mitovesicles secreted into the extracellular space of brains with mitochondrial dysfunction impair synaptic plasticity.Molecular neurodegeneration · 2024Article
- The Impact of Neurotransmitters on the Neurobiology of Neurodegenerative Diseases.International journal of molecular sciences · 2023Review
- Comparison of Monoamine Oxidase-A, Aβ Plaques, Tau, and Translocator Protein Levels in Postmortem Human Alzheimer's Disease Brain.International journal of molecular sciences · 2023Article
- Germanium Dioxide Nanoparticles Mitigate Biochemical and Molecular Changes Characterizing Alzheimer's Disease in Rats.Pharmaceutics · 2023Article
- Synthesis and Biological Evaluation ofAntioxidants (Basel, Switzerland) · 2023Article
- (Molecules (Basel, Switzerland) · 2023Article
- In silico molecular docking and molecular dynamic simulation of agarwood compounds with molecular targets of Alzheimer's disease .F1000Research · 2023Article
- Mitochondrial Interaction with Serotonin in Neurobiology and Its Implication in Alzheimer's Disease.Journal of Alzheimer's disease reports · 2023Review
- Neurotoxicity of anthracene and benz[a]anthracene involves oxidative stress-induced neuronal damage, cholinergic dysfunction and disruption of monoaminergic and purinergic enzymes.Toxicological research · 2022Article
- Soyasapogenol-B as a Potential Multitarget Therapeutic Agent for Neurodegenerative Disorders: Molecular Docking and Dynamics Study.Entropy (Basel, Switzerland) · 2022Article
- Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine.Cellular and molecular neurobiology · 2022Review
- Strategies to identify candidate repurposable drugs: COVID-19 treatment as a case example.Translational psychiatry · 2021Review
- Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.Molecules (Basel, Switzerland) · 2021Review
- Relationships between Mitochondrial Dysfunction and Neurotransmission Failure in Alzheimer's Disease.Aging and disease · 2020Review
- Current and emerging therapeutic targets of alzheimer's disease for the design of multi-target directed ligands.MedChemComm · 2019Review
- A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer's Disease.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoamine oxidase-A (MAO-A) and MAO-B have both been implicated in the pathology of Alzheimer disease (AD). We examined 60 autopsied control and AD donor brain samples to determine how well MAO function aligned with two major risk factors for AD, namely sex and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.